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1. Aims  
Topical photodynamic therapy (PDT) has become an established treatment modality for 
dermatologic conditions like actinic keratosis, Bowen's disease, in situ squamous cell 
carcinoma (SCC) and superficial basal cell carcinoma (BCC). Pain during light exposure is 
one of the main disadvantages of PDT. This thesis undertakes different approaches to 
monitoring and managing the pain problem. 
 
1. The influence of topical anaesthetic lidocaine, which is used in clinical PDT practice, 
and which may also act as a singlet oxygen quencher, was investigated on 
protoporphyrin IX (PpIX) photobleaching rate and the PDT effectiveness in vitro (paper 
I).  
 
2. The influence of topical anti-erythemal substance L-sulforaphane on PpIX production 
and pain induction during PDT was examined in vitro and in vivo (paper II).  
 
3. Different light wavelengths (violet light at 407 nm versus red light at 636 nm) for 
activation of PpIX were compared with regard to pain induction (paper III).  
 
4. The use of a penetration enhancing device, microneedles, was evaluated with respect 
to the side effects of PDT (paper IV). 
 
5. Bioimpedance spectroscopy was employed to investigate changes related to pain 
induction in the skin during light exposure in topical PDT (paper V).  
 
6. A novel method for pain monitoring, namely, measuring time from the beginning of 
light exposure until the onset of pain, was evaluated in terms of its reproducibility and 
reliability (papers III-V). 
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2. Introduction 
 
2.1 Topical photodynamic therapy (PDT) 
The story of photodynamic therapy (PDT) started around the turn of the last 
century, when Oscar Raab, Medical student of Hermann von Tappeiner, noticed that 
acridine in combination with sunlight was lethal to paramecium caudatum (1-3). This finding 
inspired von Tappeiner to continue research on light and dye induced cell death. Soon 
after, in cooperation with Albert Jesionek, a young assistant professor at the Department of 
Dermatology, University of Munich, von Tappeiner discovered that the presence of oxygen 
in the system was necessary for photosensitization to occur. They were the first to see the 
antitumor potential of photosensitization and the first to treat humans by applying eosin 
and exposing to white light lupus vulgaris, stage II syphilis and basal cell carcinoma (BCC) 
(4;5). It was about that time von Tappeiner, together with Albert Jodlbauer, introduced the 
term “photodynamic” to distinguish the process from already well known photo-processes 
occurring in photography (6;7).In 1911, Hausmann injected hematoporphyrin (Hp) into 
mice and observed erythema and oedema after sunlight exposure (8). Hp was recognized 
as a powerful photosensitizer and studied in detail. Its components were described, tumor 
localizing properties were determined and, finally, its derivatives were produced (9-12). 
The research took off and, in the 1970s, a big number of scientists joined the quest for a 
perfect photosensitizer. The milestones in PDT development are shown in Table 1.  
Table 1 Milestones in the development of PDT (1900-2010).  
Year Scientist/Company Discovery 
1900 O. Raab (2) Combination of light and acridine was toxic to 
paramecium. 
1902 Ledoux-Lebards  
(13) 
Eosin kills paramecia better in oxygen enriched flasks. 
1903 von Tappeiner and 
Jesionek (7) 
Demonstrated requirement of oxygen in 
photosensitization. 
1911 W.Hausmann (8) Hematoporphyrin a powerfull photosensitizer 
1912 Meyer-Betz (14) First injection of hematoporphyrin (into his own veins)  
1948- 
1968 
Shenek and Foote 
(15) 
The role of singlet oxygen was recognized. 
Photosensitization was divided in two mechanisms, 
Type I and type II reactions. 
1950s Figge et al. (16) Hp has tumor localizing properties 
1951 Berlin et al. (17) Excess administration of exogenous ALA bypasses the 
cellular feedback control mechanism and leads to PpIX 
accumulation. 
1955 Schwartz (18) Hp needs purification; Hp derivative with sulfuric 
acid and acetic acids 
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1961 R.L. Lipson (19) HpD has more components than Hp, but better tumor 
localizing properties than Hp 
1970s A large number of scientists joined in the search for the best photosensitizer  
1979 Moore (20) Biochemistry of porphyria showed that porphyrins 
can be produced endogenously. 
1985-
1992 
Kessel et al. (21) Diethers and diesters were central. Aggregates show 
tumor localizing properties 
1987 Malik and Lugaci 
(22) 
Use of ALA in PDT 
1987 Peng Q. (23) ALA has tumor localizing properties. 
1987 Mang et al. (24) Photobleaching of porphyrins used in PDT 
1990 Kennedy (25) First clinical trial with ALA for skin abnormalities. 
1990-
1991 
Moan et al. (26)  Short lifetime of singlet oxygen explains why PDT 
occurs close to cell and why PDT has low genotoxic 
potential. 
1998 Dougherty (27) Purifies Hp chromatographically to Photofrin. Still 
most widely used in PDT. However Photofrin has 
drawbacks: contamination with impurities, low 
absorbance at 630 nm, prolonged skin photosensitivity 
(6-8 weeks) 
1999 DUSA 
Pharmaceuticals 
(28) 
ALA under the name Levulan is approved for the 
treatment of actinic keratosis (AK). 
2002 PhotoCure ASA 
(29) 
Metvix is a photosensitive cream containing the 
methyl ester of 5-aminolevulinic acid, which has been 
developed and launched by PhotoCure in Sweden for 
the treatment of high-risk basal cell carcinoma and 
actinic keratosis 
2008 Photocure ASA, 
Galderma (30) 
Metvixia (Metvix outside US and France) in 
combination with Aktilite CL128, the LED based 
narrow band (630 nm) red light technology device has 
been approved by US Food and Drug Administration 
(FDA) for the treatment of actinic keratosis (AK), a 
pre-cancerous skin lesion. 
 
 As of today, it is known that PDT requires a target-site-localizing photosensitizer, 
light at a specific wavelength and the presence of oxygen for effectiveness. Topical PDT is 
widely studied and approved for non-melanoma conditions (31;32).  
2.2 ALA and MAL 
2.2.1 ALA 
Ever since 5-aminolevulinic acid (ALA) was first used for topical photodynamic 
application, it has been an exciting therapeutic modality for dermatologists. Due to its small 
molecular weight (167.6 Da), the ALA molecules can penetrate through stratum corneum 
(33;34). Moreover, ALA is a natural compound with a fast clearance from the body (about 
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24- 48 h) leading to low systemic toxicity (27). Although ALA is a hydrophilic molecule, 
since early 1990s, many clinical studies have been published for actinic keratosis, Bowen’s 
disease, superficial BCC and SCC, demonstrating a clearance rate of 80-100%, 90-100%, 80-
100% and 67-92%, respectively (35).  
As ALA passes through stratum corneum and enters into neoplastic cells, it interacts 
with the heme biosynthesis pathway which takes place in every cell of the body (with the 
exception of erytrocytes) and is very tightly regulated. Normally, the concentration of 
intermediate products is too low for photosensitization. When exogenous ALA enters into a 
cell, it bypasses the negative feedback controls allowing for the photosensitizer to 
accumulate (figure 1).  
The heme synthesis pathway has two rate-limiting steps. The first one is the 
condensation of succynyl coenzyme A (succynyl CoA) and glicyne into ALA. Addition of 
exogenous ALA bypasses this process. The second rate-limiting step is the incorporation of 
iron into the PpIX chain. This step is catalyzed by the enzyme ferrochelataze. However, 
since there is an overabundance of ALA and, thus, PpIX and only a limited amount of iron, 
the PpIX accumulates in concentrations sufficient for photosensitization. 
 
Figure 1. Heme biosynthesis pathway with marked pathway of PpIX accumulation after 
addition of exogenous ALA. Adapted from Kufe et al. (36) 
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In addition to being natural, chemically pure and having minimal dark toxicity, 
PpIX has another advantage: a part of its absorption spectrum lies in the tissue optical 
window (600- 1300 nm). Thus, activation with deeper penetrating light wavelengths is 
possible (figure 2). When excited by the absorbed light, PpIX can decay back to its ground 
state either by emitting fluorescence (this phenomenon is widely used for tumor 
visualization and diagnosis) or by reacting with the surrounding biomolecules or molecular 
oxygen. The latter reactions lead to formation of reactive radicals, mainly singlet oxygen, 
which, in turn, react with lipids, proteins, nucleic acid etc. causing lethal damages to cells.  
 
Figure 2. Tissue optical window (i.e. range of wavelengths where light has maximum depth 
of penetration into tissue) and the protoporphyrin IX (PpIX), hemoglobin (Hb), 
oxyhemoglobin (HbO2), melanin and water absorbance spectra. Based on Hamblin,M.R. (37)  
 
2.2.2 MAL 
The two main drawbacks of ALA-PDT are the shallow penetration depth of ALA 
and transient local symptoms during and after light exposure, like stinging, burning, 
itching, erythema and edema. To counteract these limitations the methyl ester of ALA 
(MAL) was introduced.  
MAL, being more lipophilic than ALA, was thought to penetrate deeper into tissues 
(23;38). However, it has been shown that MAL-induced PpIX is being produced with a time 
lag (39). Possibly, MAL is bound to stratum corneum and other lipophilic compartments, 
which significantly slows down its penetration (40). Therefore higher concentrations of 
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MAL are needed for equal production of PpIX as from ALA in normal healthy skin (41). On 
the other hand, MAL has better tumor localizing properties and does not lead to systemic 
photosensitization after local topical application (39). It has also been shown that MAL 
causes less pain sensations than ALA (42). Although not all findings support this statement 
(43), it is generally believed that MAL-PDT is less painful than ALA-PDT due to its 
transport mechanisms (44) and tissue localization pattern (45;46). ALA has a structure that 
is similar to aminobutyric acid (GABA), and might be transported into a cell by the same 
carrier systems as this neurotransmitter (44). MAL, on the other hand, might be taken up by 
more than one active transport mechanism (47). The larger uptake of ALA into nerve cells 
via GABA receptors may explain the more intense pain experienced by patients during 
ALA-PDT as compared to MAL-PDT (44).   
MAL, under the name Metvix,  is approved in Americas for the treatment of actinic 
keratosis and many countries in Europe and Asia for the treatment of actinic keratosis, BCC 
and Bowen’s disease (48) and non-melanotic conditions like acne, photodamaged skin and 
for photorejuvenation (31).  
The introduction of ALA and MAL was a major breakthrough in PDT as it offered 
shorter cutaneous photosensitivity (27) and higher tumor selectivity (49). Clearance of 
ALA- and MAL- induced PpIX from the body takes only up to 48 h as compared to 
Photofrin which has a retention varying from 6 days to 3 months (27). For cutaneous 
applications, 5-aminolevulinic acid- PDT (ALA-PDT) (Levulan ® Kerastick ™ ) is approved 
with blue light (BLU-U® Blue Light Photodynamic Therapy Illuminator, Model 4170) (50), 
while methyl 5-aminolevulinate- PDT (MAL-PDT) (Metvix ®) is approved with Aktilite 
CL128 ™, LED based narrow band (630 nm) red light technology device (51). 
2.3 Mechanisms of PDT  
As described above, when the ALA- or MAL-induced photosensitizer PpIX absorbs 
light, it reaches an excited state. The excited photosensitizer transfers its energy to the 
ground level oxygen present in the tissue. This creates singlet oxygen, which can kill tumor 
cells directly by induction of necrosis and/or apoptosis, can cause vasculature shutdown or 
immune responses (52). The severity of the tissue responses depends both on the lesion 
type and the treatment regimen (figure 3).   
2.3.1 Apoptosis and necrosis 
Apoptosis is a controlled-by-cell suicide that results form irreparable damage 
suffered by the cells. In most cases apoptosis is dependent on the p53 protein. Most of 
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neoplastic tissues, however, are characterized by lack of p53 activity, further distinguishing 
them from the surrounding normal tissues. PDT has the advantage that it can lead to p53 
independent apoptosis (53;54), which is a “tidy” mechanism that does not result in 
inflammation.  
Necrosis results in cellular membrane breakage and leakage of the cell content into 
the extracellular space, inducing immune responses and inflammation, which is also 
observed after PDT. In vitro studies demonstrate that the mode of cell death depends on the 
extent of initial cell damage (55;56) 
2.3.2 Immune responses 
PDT effects on the immune system can be either immunosuppressive or 
immunostimulatory (52). Cells dead through necrosis attract leukocytes into the tumor site 
and increase antigen presentation (52). The acute inflammatory response induced by PDT 
attracts dendritic cells, which phagocyte the destroyed cells, mature under the influence of 
locally released cytokines and present the antigen to naive T cells in the local lymph nodes. 
This leads to maturation of T cells, which subsequently become effector T cells, migrate to 
the tumor site and kill the tumor cells (figure 3). At this point the tumor environment can 
be described as a site of chronic inflammation (57). In 1994, Canti et al. (58) showed that 
mice with fibrosarcomas treated with either PDT with aluminum disulfonated 
phthalocyanine (AIS2Pc) or surgery, had the same survival rate. However, when re-
challenged with the fibrosarcomas, only the mice treated with PDT in the first place 
survived. Subsequent exposure of the surviving mice to another type of cancer proved 
lethal. This excellent study showed that next to short-term tumor ablation, PDT can induce 
long-term, specific anti-tumor immunity. 
 Paradoxically, PDT can also induce immunosupression. PDT with shallow 
penetrating blue light acts via interleukin 4 (IL4) activation while PDT involving deep 
penetrating red light acts via the activation of interleukin 10 (IL10) (52). Both pathways lead 
to short term (up to 28 days) immunosupression. In contrast to UV, surgery, radiotherapy 
and chemotherapy which suppresses both short- and long-term responses, PDT does not 
induce long-term immunosupression (51). 
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Figure 3. The action mechanism of PDT on tumors. The excited photosensitizer (PS*) transfers 
its energy onto the molecular oxygen (3O2) in its proximity. The singlet oxygen (1O2) reacts 
with biomolecules and leads to damage that can cause tumor cell death by apoptosis and/or 
necrosis; microvasculature responses or inflammation. Adapted from Castano et al. (52) 
 
2.3.3 Vascular responses 
  Vascular responses occur immediately after PDT as a result of direct vasculature 
damage and/or nitric oxide mediated vasoconstriction /vasodilatation, release of 
vasoactive substances or edema (40;59;60). Vascular damage leads to hypoxia through nitric 
oxide inhibition and a subsequent contraction of smooth muscle cells surrounding the 
endothelium of blood vessels (61). Nitric oxide inhibition results also from the PDT oxygen 
consumption, as nitric oxide is biosynthesized endogenously from L-arginine, oxygen and 
NADPH by various nitric oxide synthase (NOS) enzymes (61;62). There seems to be a 
difference in response between normal and tumor microvessels, as normal vessels in the 
margin of the tumor have a better control over the smooth muscle cells than do tumor 
vessels (60). On the other hand, a large increase in tissue oxygenation (from 3 up to 9.5 
mmHg) after ALA-PDT was reported by Pogue et al. (63). The oxygenation returned to 
baseline levels after 48 h after PDT. The authors explained the results by a decrease in local 
oxygen metabolic consumption due to cellular damage (63).  
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 The tissue oxygen status during light exposure is an indication of tumor hypoxia, 
PpIX photobleaching (i.e. the therapy effectiveness) and, possibly, PDT-induced pain. 
2.4 PDT-induced pain  
2.4.1 Factors influencing pain  
Pain during topical PDT occurs during light exposure is experienced to varying 
degree by the majority of patients and may last for some hours (usually it disappears on the 
same day) (31;32;64-67). A number of different factors influence the pain during topical 
PDT, such as the localization, size and the type of lesion, PpIX amount, its localization, the 
type of PpIX precursor, fluence, fluence rate, fractionated light delivery, light source, 
wavelength, temperature increase, skin type, patient’s age and sex (figure 4). The influence 
of some of them has neither been clearly confirmed nor disproved as the available 
knowledge is conflicting.  
 
 
Figure 4. Factors influencing PDT-induced pain. The influence of encircled factors is not confirmed 
as the existing evidence is conflicting. 
2.4.1.1. Total PpIX amount 
Light exposure of PpIX leads to creation of 1O2, which in turn leads to cell damage 
and, consequently, cell death. A correlation between the intensity of pain and PpIX amount 
in the tissue (68), as well as a correlation between the intensity of pain and photobleaching 
rate has been demonstrated (43). However, not all studies report such a correlation 
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(45;64;69). Other factors, intrinsic to the treated disease, such as the type and localization of 
a lesion, were reported co-determinants of pain with the PpIX levels (43;70;71).  
2.4.1.2. Type of PpIX precursors (ALA and MAL) 
Different precursors of PpIX may act differently with regard to their uptake by cells, 
penetration depth, intra-tissue localization of PpIX production, retention time, systemic 
toxicity, etc. Therefore, it is of interest to investigate the differences between the ALA-PpIX-
induced pain and MAL-PpIX-induced pain. Here again, conflicting evidence has been 
found. ALA is transported through different pathways than ALA esters. In addition it has 
been suggested that long-chain ALA esters are taken up more efficiently than ALA, 
possibly by passive diffusion (44). Rud et al (44) showed that transport of ALA is Na+, Cl− 
and energy-dependent. These data, together with the fact that ALA lowers blood pressure, 
just like GABA, point to GABA receptors as possible transporters of ALA into cells (72). 
Since GABA transporters are found in peripheral neurons, the uptake of ALA, but not 
MAL, could explain more pain sensations during ALA-PDT than MAL-PDT. Neoplastic 
cells, due to their high metabolism, have increased demands for amino acids, thus 
expressing a higher number of receptors. This leads to selective uptake of ALA by 
neoplastic tissue and the well known selectivity of ALA-PDT. However, when investigating 
the pain sensations during ALA- and MAL-PDT with the same PpIX levels, no difference 
was found (43). These findings point back to the importance of the total PpIX amount in the 
induction of PDT-related pain. 
2.4.1.3. Localization, size and type of lesion 
There is consensus in the literature that localization, size and type of lesion 
influence the severity of pain during PDT (66;69;73;74). Treatment of well-innervated areas, 
like face, hands and perineal region results in more pain than treatment of other regions 
(69). As for the type of lesion, PDT of psoriasis results in the highest pain scores, followed 
by actinic keratosis, while BCC seems to be relatively mild in pain (73). Possibly, this is due 
to different levels of keratinization resulting in different PpXI accumulation patterns in the 
lesions (75). Treatment of multiple lesions or large areas also results in more intense PDT-
pain (66). The increase in pain with increase in the treated area may be explained by the 
increase in total malignant cells present in the treatment area (69). However, a study by von 
Oosten et al. demonstrated no difference in pain between different sized lesions, nor 
between lesions differently located (74).  
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2.4.1.4. Temperature increase 
Skin temperature increases during light exposure (70;76), and may influence the 
severity of experienced discomfort. Since patients characterize the pain as a burning 
sensation, it has been concluded that it is the absorbed energy delivered by light exposure 
that leads to local temperature increase (40). Tumors are more sensitive to temperature 
increase above 41°C than normal, surrounding tissue (77). Warloe et al. showed an increase 
in temperature of skin surface exposed to light at 630 nm with fluence rate of 100-150 
mW/cm2 up to 40°C (76). However, the temperature increase from the increased blood 
perfusion has not been differentiated. Another study showed that increase in skin 
temperature above 40°C is possible only when associated with fluence rates higher than 150 
mW/cm2 (70). In clinical applications, fluence rates higher than 75 mW/ cm2 are rarely 
used. Thus, the light exposure could not be the sole reason for the pain. 
2.4.1.5. Fluence and fluence rate 
The fluence rate and total delivered dose influence pain induction and its intensity 
(68;78;79). Cottrell et al. suggested a pain threshold at 60 mW/cm2, below which the 
majority of discomfort was alleviated (78). Light exposure at low fluences (9 J/cm2) 
prevented fast oxygen depletion and immediate immune response resulting in 
vasoconstriction, which would impair continuous oxygen supply. After bleaching of 80% 
PpIX with low fluence rates, an increase in fluence rate did not result in pain increase and 
allowed for delivery of full treatment dose (78). Recently, a study combining low fluence 
rates and a fractionated regimen demonstrated that low fluence rates result in more 
efficient use of the available oxygen, i.e. increased photobleaching rate (80). Therefore, the 
lower the fluence rate, the higher the photobleaching efficiency with a theoretical 
maximum below 1 mW/cm2 (80;81). However, lowering of the fluence rate results in 
prolonged treatment, and thus may be of limited clinical application value.  
2.4.1.6. Fractionated light delivery 
Introducing a dark period in the PDT treatment regimen has been shown to give 
additional PpIX synthesis from still available ALA (82-84). Additionally, fractionation 
enables re-oxygenation of the treated area, thereby increasing the effect of PDT (85). In 
2006, de Haas et al. (83) showed that a 2-hours dark period between exposures of 20 and 80 
J/cm2 increased the efficiency of ALA-PDT in BCC patients up to 97%. In 2007, Lindeburg 
et al. concluded that in patients with AK and BCC given Metvix-PDT with two light 
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exposure fractions, the second one was significantly more painful and became the therapy 
limiting factor (86).  
2.4.1.7. Fitzpatrick skin type 
There is a limited number of studies of a possible influence of skin type on the 
severity of PDT-related pain, and the data are conflicting. A recent study showed a 
statistical analysis of factors predictive for pain during ALA- and MAL-PDT from over 100 
patients (64). The results of this study showed that Bowen’s disease (BD) and AK patients 
with skin types I and II reported higher pain scores than patients with skin type III. 
Another study on 60 patients diagnosed with BCC, BD and AK reported no correlation 
between severity of pain and skin type (69).  
2.4.1.8. Wavelength 
The choice of wavelength for topical PDT should be made by taking into account 
the thickness of the treated lesion and the absorption characteristics of the tissue to be 
destroyed (87). Green light (543-548 nm) has been shown to be equally effective and less 
painful than red light in ALA-PDT in patients with multiple solar keratoses (88). Also full 
spectrum visible light at high light doses proved effective for ALA-PDT treatment of solar 
keratoses (89). Another study showed that green light, although less painful, was also less 
effective than red light (630 +/- 15 nm) in ALA-PDT of Bowen’s disease (90). MAL-PDT of 
AK with red or blue light showed no difference in effectiveness nor in pain (91). Combined 
violet and subsequently red light showed positive results in melanotic melanomas, where 
violet light was used to bleach some of the melanin from above the melanomas before 
commencing red light PDT (92). 
2.4.1.9. Patient’s sex and age 
Male patients seem to experience more pain during ALA-PDT than females (93). 
However, a number of other studies did not confirm this finding (64;69;74;94). There is 
agreement in the literature that the patient’s age has no significant influence on the 
experienced level of pain (64;69;74;93;94). 
2.4.2 Possible mechanisms of PDT-induced pain 
 The mechanisms of PDT-induced pain remain largely unknown. However, some 
theories exist that can help explain certain features of this unpleasant sensation.  
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2.4.2.1 Peripheral nerve stimulation 
The pain appearance is often described as neurogenic, i.e. associated with 
peripheral nerve stimulation (95;96). A study on a canine model showed a correlation 
between the ALA-PDT-induced peripheral nerve injury and light dose (97). Generally, pain 
is believed to be mediated through the non-myelinated C-fibres (figure 5), involving 
substance P and other neurotransmitters (98). However, desensitization of nerve endings 
by depleting substance P and other neurotransmitters by repeated contact with capsaicin 
(chili pepper) during ALA-PDT of AK patients showed no pain-relieving effects (98). 
Moreover, no substance P was detected in relation to ALA- and MAL-PDT in healthy 
volunteers (71). 
2.4.2.2 GABA receptors 
Peripheral nerve stimulation theory may be in line with, previously mentioned, 
transport of ALA by GABA receptors into the nerve endings (45), which upon light 
exposure become activated. This does not explain the MAL-PDT induced pain, since MAL 
is not transported into the nerve endings. On the other hand, when taking into account 
ALA- and MAL-induced PpIX fluorescence patterns, it shows that ALA-PpIX displays a 
uniform fluorescence over the applied area, while MAL-PpIX appears in discrete spots (66). 
It is logical to assume that those spots are hair follicles and sebaceous glands where PpIX is 
located. The close proximity of nerve endings innervating the hair follicles to the place of 
photodynamic action may be an explanation for MAL-PDT induced pain (figure 5). 
 
Figure 5. In skin there are 3 types of terminals of primary sensory afferent neurons: 1) 
Myelinated Aβ fibers which respond to low-threshold, non-painful stimuli, e.g. touch. 2) Aδ 
fibers, with thin myelination, respond to both non-painful and painful stimuli and 3) C-fibers, 
non-myelinated fibers, that respond to high- threshold painful stimuli. There are two 
subtypes of C-fibers: 1) non-peptidergic, localized in stratum granulosum, which respond to 
mechanical stimuli and 2) peptidergic C-fibers, localized in stratum spinosum, responding to 
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heat pain stimuli. DRG stands for dorsal root ganglion. 
 
2.4.2.3 Release of mediators of inflammation  
Even though MAL is not taken up into the nerve endings, reactive oxygen species 
(ROS) produced during light exposure may cause cell damage and/or degranulation of 
mast cells leading to release of inflammatory mediators, e.g. histamine (99). Mast cell 
degranulation products, as well as potassium ions, can activate Aδ and C fibers in the skin 
(figure 5). Histamine is directly involved in the immediate PDT-pain response (99), while 
bradykinin, serotonin and prostaglandins are probably involved in the later-occurring 
inflammation.  
2.4.2.4 TRPV1 receptor activation 
The capsaicin receptor TRPV1 (transient receptor potential cation channel, 
subfamily V, member 1) is a non-selective, calcium-permeable cation channel that is 
expressed on peripheral terminals of small to medium diameter sensory neurons and can 
be activated by, among others, heat stimuli (100). The skin temperature rise caused by 
energy absorption by PpIX during ALA-PDT is insufficient for actual tissue damage (76). 
However, the light energy absorption by melanin is much larger than the energy 
absorption by PpIX and adds to the temperature increase (40). This can provide an 
explanation for TRPV1 receptor activation during light exposure during topical PDT.  
 
2.5 Topical PDT-pain management 
 Many attempts to reduce the PDT associated pain have been made, as summarized 
in figure 6 and table 2, and outlined in more detail below.  
2.5.1 Topical anesthesia 
Topical anesthesia was the first method employed for this task (66). Unfortunately, 
local topical anesthesia with lidocaine, tetracaine, prilocaine, morphine and capsaicin 
proved to be ineffective in relieving the PDT-induced pain (table 2). The acidic pH of the 
ALA and MAL creams may counteract the actions of topical anesthetics (66). Possibly there 
may be a saturation of the skin with ALA and MAL creams preventing the anesthetics from 
penetrating into the tissue (66). Moreover, local anesthetics block only ion channel-
mediated painful stimuli and cannot prevent ion leakage from membranes broken by 
photodynamic action (70). Anesthetics injected deeper can prevent generation of nerve 
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signals, since these nerves are not reached by the photodynamic effect and, thus, remain 
intact (70).  
 
Figure 6. PDT-induced pain management pathways. Exclamation mark (!) follows methods 
shown to be successful in PDT-pain relief. Question mark (?) stands for methods where the 
available data are inconclusive. Topical anesthesia is still used for PDT-pain relief, yet the 
benefit of its use is doubtful. 
 
2.5.2 Electrical nerve stimulation 
The mechanism behind the effect of transcutaneous electrical nerve stimulation is 
based on gate-controlled blocking of nerve fibers in the proximity of the treated area (101). 
Possible effectiveness of this method has been demonstrated on AK patients during 
Metvix-PDT (101). 
2.5.3 Cooling of the treated area 
 Cooling with air, water spray or cold packs of the treated site is, next to nerve 
blocks and subcutaneous injections, the only efficient method for pain relief during light 
exposure during topical PDT. The reason for its success is not known. However, there are 
hypotheses that reduction in temperature lowers the tissue metabolism, thus reducing the 
effects of injury, and causing vasoconstriction, which in turn limits the inflow of 
inflammatory mediators (66). Topical cooling increases the threshold for pain stimuli and 
inhibits activation of pain pathways by stimulating myelinated Aδ fibers (102). Moreover, 
low temperatures may inhibit the activation of TRPV1 receptors, thus decreasing the pain 
sensations. Additionally, cooling can activate cold and menthol receptor TRPM8 (transient 
receptor potential cation channel, subfamily M, member 8) (103). Unfortunately, the 
effectiveness of cooling in pain reduction, during MAL-PDT of AK, BCC and BD seems to 
reduce PpIX photobleaching, and thus, PDT efficacy (104). 
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2.5.4 Nerve blocks 
 A number of studies showed a benefit of nerve blocks in Metvix-PDT for extensive 
facial AK (105;106). The nerve block method was reported to be superior to cooling with air 
for extensive AK treated with Metvix-PDT (107). However, pain relief with nerve blocks 
presents a risk for potential vessel trauma or nerve injury resulting in paresis (108). 
2.5.5 Subcutaneous infiltration 
 Subcutaneous infiltration anesthesia (SIA) was reported to be effective in alleviating 
pain during Metvix-PDT treatment of patients with actinic chelitis (109) and ALA-PDT 
treatment of extensive facial AK (110). SIA is not a preferred method for pain relief in 
proximity of eyes due to a risk for vision impairing by swelling of the eyelids (110). 
Moreover, the need for multiple injection sites presents a risk for infections (110). 
2.5.6 Hypnosis  
 Pain relief with the use of hypnosis has been demonstrated for treatment of low 
back pain (111). Hypnosis for pain reduction during ALA-PDT was evaluated on two AK 
patients. It was concluded that fear or doubt in its effectiveness can impair the pain relief 
(70). 
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Table 2 PDT-related pain management methods and their outcome.  
Pain management 
method 
Pub. 
year Authors N Outcome 
To
pi
ca
l a
ne
st
he
si
a EMLA 2006 Langan and Collins (112) 14 
No benefit 
lidocaine 2004 Touma et al. (113) 18 Minor benefit 
tetracaine 2003 Holmes et al. (95) 42 No benefit 
morphine 2006 Skiveren et al. (114) 28 No benefit 
capsaicin 2006 Sandberg et al. (98) 91 No benefit 
Nerve blocks 2008 Paoli et al. (106) 16 Beneficial for 
motivated 
patients 
Subcutaneous 
infiltration 2007 Borelli et al. (110) 16 
Cooling 2004 Pagliaro et al. (115) 26 
Beneficial, but 
may interfere 
with treatment 
outcome 
Hypnosis 2003 Algermissen et al. (70) 2 
Use limited to 
the patients 
who believe in 
the effect of 
hypnosis 
Electrical nerve 
stimulation 2008 Halldin et al. (101) 14 
Minor, but 
statistically 
significant 
benefit 
N stands for the number of patients in the study. 
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3. General experimental considerations 
3.1 Chemicals 
5-aminolevulinic acid hydrochloride (ALA) was used as an active compound in 
papers I-V. In addition, methyl 5-aminolevulinate hydrochloride (MAL) was used in papers 
III and IV. Moreover, lidocaine hydrochloride, β-carotene and protoporphyrin IX (PpIX) 
were used in paper I. PpIX was, together with (R)L-sulforaphane (SF), also used as an 
active compound in paper II.   
In cell work (papers I and II) phosphate-buffered saline (PBS), dimethyl sulfoxide 
(DMSO), RPMI medium, penicillin/streptomycin solution, L-glutamine, trypsin/EDTA 
solution, foetal calf serum (FCS) (paper I) or foetal bovine serum (FBS) (paper II) were used.  
For experimental work involving human volunteers (papers III-V), the active 
compounds were diluted in cream base Unguentum M to reach their final concentration. 
Molecular weights and chemical structures of the active compounds are presented in 
Table 3.  
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Table 3. Structures and molecular weights of the active compounds used. 
Compound 
MW 
(Da) 
Chemical structure 
ALA HCl 167.6 C5H10ClNO3 
 
MAL  181.6 C6H11ClNO3 
 
PpIX 562.7 C34H34N4O4 
 
Lidocaine 234.3 C14H22N2O 
 
β-carotene 536.8 C40H56 
 
SF 177.3 C6H11NOS2 
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3.2 Cells 
The human cell lines WiDr (paper I) and A431 (paper II) were used in this work. 
The WiDr cell line has been derived from a primary adenocarcinoma of the human 
rectosigmoid colon of a 78-year-old female in 1978 by Noguci et al. (116). This cell line is 
reprted to have a doubling time of 15 h and a plating efficiency of 51%. Cells attach slowly 
to the substratum, remain rounded and loosely adherent for 24 to 48 h before flattening into 
a monolayer (116). The WiDr cell line has a mutation in the gene encoding p53 (117), and 
after ALA-PDT die only through necrosis (118). 
  The epidermoid carcinoma cell line A431 was in 1973 derived from a solid tumor 
from an 85-year-old female. It is one of a series of cell lines established from solid tumors 
by Giard et al. (119) Although the A431 cell line has a mutated p53 gene, it may die also by 
apoptosis (120).  
3.3 Animal work 
The part of the work involving an animal (paper III) was approved by the National 
Animal Authority (Norway) and was performed according to the European Convention for 
the Protection of Vertebrate Animals used for Experimental and other Scientific Purposes 
(CETS). Three separate samples of skin were obtained from one female 12 weeks old NCR 
nude mouse. The mouse was obtained from The Norwegian Radium Hospital (Oslo, 
Norway).  
During the PpIX fluorescence decay experiment (paper III), which lasted for 3 
hours, the mouse was housed alone in the cage in subdued light and was provided with 
food and water ad libitum. The cage was placed in a scantainer providing 22ºC and 40-50% 
humidity. Before i.p. injection of 200 mg/kg ALA in PBS at pH 5, the mouse was 
anesthetized with Sevoflurane. After 3 hours the mouse was sacrificed by cervical 
dislocation under Sevoflurane anesthesia.  
3.4 Human volunteers 
The work involving healthy human volunteers (papers III- V) was approved by the 
Regional Committee for medical and health research (Regional komité for medisinsk og 
helsefaglig forskningsetikk, Helseregion Sør, avdeling B, REK Sør B; ref.nr. S-07434b). 
The volunteers were a random group of healthy persons. No discrimination of age, 
gender, religion, skin type or other was made. The test spots were marked on the skin of 
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the volunteers with a simple non-fluorescent marker and covered with light-impenetrable 
occlusive dressing. Thus, no restrictions on physical or other activities were made upon the 
test subjects.   
3.5 Light exposure 
 
An in-house built lamp with four fluorescent tubes was used for the in vitro studies 
(papers I and II).  The lamp emits light in the region 400–460 nm and with a peak at 420 nm 
(figure 7). Cells grown in culture dishes were placed on the lamp for light exposure. The 
fluence rate at the position of the cells was 10 ± 0.5 mW/cm2 as measured with a 
photodiode (NewPort, Model 1815-C, Irvine, CA).   
 
Figure 7 Spectrum of the fluorescent blue lamp used for light exposure of cells (papers I and II). The 
lamp emits light in the region 400–460 nm with a peak at 420 nm 
A red LED (light emitting diodes) lamp was used for the in vivo studies (papers II 
and IV). The lamp emits in the spectral range 580-670 nm, and has a peak at 632 nm (figure 
8). The lamp was placed 5 cm above the skin surface. The fluence rate at the surface of the 
skin was 90 ± 4 mW/cm2. Similar fluence rates are continually being used in clinical PDT. 
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Figure 8 Emission spectrum of the red LED lamp used for exposure of human skin to light (papers II 
and IV). The lamp emits in the spectral range 580-670 nm, and has a peak at 632 nm 
A red laser, λ= 632 nm, (papers III and V) and a violet laser, λ= 405 nm, (paper III) 
were used in the in vivo studies. The violet laser was in-house built consisting of a PMM-
608G violet laser diode (405 nm, Photonic Products,UK) which was fitted with an 
expanding lens and a 20 cm2 aluminum heat-sink and powered by an adjustable direct 
current power supply produced in our workshop. 
 In order to control the violet laser output, a calibration curve was made by 
measuring the laser output with a PowerMeter photodiode (NewPort, Model 1815-C, 
Irvine, Calif., USA) as a function of the applied current. The calibration curve is shown in 
figure 9. 
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Figure 9 Calibration curve for the in-house built violet laser. 
3.6 Pain assessment 
 Pain was assessed by measuring the exact time (in seconds) from the beginning of 
light exposure to the onset of pain (paper IV and V). Each volunteer had an additional 
control spot where cream without active compound was exposed to light and time for pain 
to occur was measured. Thus, each of the volunteers served as their own control. The 
volunteers did not know in advance which of the spots contained active compound and 
which of the spots served as control. 
3.7 Reflectance spectroscopy 
Erythema index (papers III and IV) was measured using a narrowband reflectance 
spectrometer DermaSpectrometer®. This instrument applies light from diodes emitting at 
568 nm (green) and 655 nm (red). An erythema index is computed from the intensity of the 
reflected light. 
3.8 Fluorescence spectroscopy 
The fluorescence of porphyrins produced in the skin was measured in all spots in all 
volunteers (papers II-V) after cream removal using a fiber-optic probe coupled to a 
spectrofluorimeter (LS50B, PerkinElmer, Norwalk, CT). Excitation light was set on 407 nm, 
while the emission spectra were in the range of 560-700 nm, thus ensuring that the major 
part of the recorded fluorescence is related to PpIX molecules accumulated in the skin.  
The PpIX in solutions (papers I and II) as well as cell suspensions (papers I and II) 
were exposed to light and PpIX fluorescence was measured in cuvettes placed directly in 
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the standard cuvette holder of a luminescence spectrometer (Perkin Elmer LS45 Norwalk, 
Conn., USA). The fluorescence background (autofluorescence) of the cells without PpIX 
was recorded and subtracted from the fluorescence data.  
3.9 Statistical analyses 
Data are presented as means +/- S.E. (standard error). Experiments in solutions and 
in cells are shown as means from at least three independent experiments, all done in 
triplicates. Work performed on volunteers is presented as means of 10 volunteers. The 
Student’s t-test was used to evaluate significant differences between data points in cells and 
solutions. The Student’s paired t-test was used for comparison of data obtained from 
volunteers, each volunteer serving as his own control. Values of p < 0.05 were considered as 
indicating significant differences. In all papers calculations were performed using 
SigmaPlot calculating software. Additionally, in paper V, curve smoothing and artefacts 
removal was done in MatLab using custom filters.  
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4. Summary of the publications 
4.1 Publication I: The effect of local anesthetic lidocaine on PpIX 
photobleaching and outcome of ALA-PDT in vitro 
Introduction: Lidocaine is used topically to relieve itching, burning and pain during light 
exposure during topical PDT. It has been reported that lidocaine may act as a singlet 
oxygen quencher. 
Aim: The main goal of this study was to investigate the potential singlet oxygen scavenging 
properties of lidocaine, as such properties would directly influence the outcome of 
photodynamic treatment.  
Methods: The influence of lidocaine on PpIX monomerization in solution and on PpIX 
photobleaching in DMSO and in WiDr cells was measured by fluorescence spectroscopy. 
The effect of lidocaine on PDT outcome was evaluated by measuring the colony- forming 
ability of the WiDr cells.  
Results: Lidocaine concentrations in the range 0.2 - 5 mM increased PpIX fluorescence, 
possibly by increasing its monomerization. Photobleaching rates of PpIX in solutions were 
increased in the presence of lidocaine, although not significantly. Lidocaine had no 
influence on PpIX photobleaching or on PDT efficiency in WiDr cells. 
Conclusions: Our in vitro study showed no influence of lidocaine on PpIX photobleaching, or 
on PDT outcome. 
4.2 Publication II: Effect of (R)L-sulforaphane on ALA-PDT 
Introduction: It has been demonstrated that (R)L-sulforaphane (SF), which is derived from 
broccoli sprouts, reduces the skin redness and inflammation caused by exposure to 
ultraviolet (UV) radiation.  
Aim: The aim of this investigation was to evaluate the impact of (R)L-sulforaphane (SF) on 
PpIX production and photobleaching in vitro, in solutions and in A431 cells, and in vivo, in 
human skin.  
Methods: The influence of SF on PpIX fluorescence and photobleaching in solutions was 
measured by fluorescence spectroscopy. The dark toxicity of SF in A431 cells, as well as the 
influence of SF on ALA-PDT outcome, was determined by means of colony assay. PpIX 
photobleaching in A431 cells and PpIX production after topical application of ALA and /or 
ALA in conjunction with SF in healthy human skin were measured by fluorescence 
spectroscopy. 
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Results: PpIX fluorescence and photobleaching in solution were unaffected by the presence 
of SF. Neither did SF influence PpIX photobleaching, nor did it influence ALA-PDT 
outcome in A431 cells in concentrations below 80 μm/L. Above this concentration, SF 
caused cell detachment from the substratum. SF increased PpIX production in healthy 
human skin. 
Conclusions: (R)L-sulforaphane increased the PpIX production in human skin, but not in 
A431 cells. It did not influence the PDT outcome. Thus, it presents a safe modality for an 
anti-erythemal addition to the treatment. 
4.3 Publication III: Topical ALA- and MAL- based PDT with red and violet 
light: influence of wavelength on pain and erythema. 
Introduction: PpIX can be activated by light of different wavelengths. Red light penetrates 
deep into tissue, but is not optimal for PpIX activation. Violet light activates PpIX 
efficiently, but due to its limited penetration it can be used only for superficial lesions. 
Aim: The aim of this study was to determine if light wavelength has influence on pain and 
erythema induction during topical PDT with ALA and MAL. 
Methods: Violet and red lasers were calibrated to give the same rate of PpIX photobleaching. 
The PpIX photobleaching rate was determined by monitoring real-time PpIX fluorescence 
decay curves in murine skin. ALA- and MAL-PDT were performed on healthy skin of 
volunteers. Time was measured in seconds from the beginning of light exposure until the 
onset of pain. Erythema was followed up to 24 h after light exposure by means of 
reflectance spectroscopy. 
Results: No difference in MAL-PDT induced pain and erythema was observed for light of 
different wavelengths. In the case of ALA-PDT, however, red light induced more pain and 
longer persisting erythema than violet light. 
Conclusions: As far as pain and erythema are concerned, red light induced more side effects 
than violet light during ALA-PDT. In the case of MAL-PDT, the wavelength did not 
influence the side effects. 
4.4 Publication IV: Microneedle pre-treatment of human skin improves ALA- 
and MAL-induced PpIX production for topical PDT without increase in pain 
or erythema. 
Introduction: The efficiency of microneedles for transdermal ALA and MAL delivery has 
been demonstrated in mouse skin. However, mouse and human skin differ significantly.  
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Aim: This investigation was performed in order to evaluate microneedles as a mechanical 
means of improving the transdermal drug delivery for topical ALA- and MAL-PDT in 
human volunteers, as well as to evaluate its impact on the severity of PDT-related side 
effects. 
Methods: PpIX fluorescence in healthy human skin was measured using fluorescence 
spectroscopy. The transdermal water loss was determined by moisture probe readings of 
humidity in a chamber attached to the skin of volunteers. Pain was measured in seconds 
from the beginning of light exposure till the onset of pain. Erythema was monitored for up 
to 6 h after light exposure using reflectance spectroscopy.  
Results: Microneedles were effective in improving the transdermal drug delivery, which 
resulted in increased PpIX fluorescence after 4 h incubation, both with ALA and MAL, in 
concentrations below 16%. It did not improve the PpIX production after application of 16% 
ALA and MAL. The use of microneedles did not increase the severity of pain or erythema. 
Conclusions: The use of microneedles allows for reduction in prodrug concentration and 
incubation time without loss of effectiveness or increase in the severity of PDT-induced 
side effects. 
4.5 Publication V:  Bioimpedance for pain monitoring during cutaneous PDT.  
Introduction: Electrical impedance spectroscopy is widely used to characterize the electrical 
properties of a number of human and animal tissues.  
Aim: The purpose of this study was to evaluate the usefulness of bioimpedance 
spectroscopy as a tool for recording real-time PDT-induced changes in the skin impedance 
related to pain appearance during light exposure.  
Methods: The biompedance measurements were taken with a four-electrode set up, during 
topical photodynamic treatment of healthy human volunteers at frequencies of 10 Hz and 
100 kHz. ALA-PpIX production was monitored with fluorescence spectroscopy. 
Results: A significant drop in skin impedance both at low and high frequencies was 
observed from the moment of pain occurrence. The decrease was steeper at the low 
frequency than at the high frequency. A correlation between the total PpIX fluorescence 
and the occurrence of pain was observed, as well as a correlation between the absolute 
bioimpedance drop and the time to pain onset.  
Conclusions: Bioimpedance measurements are a relevant tool for monitoring real-time 
changes in human skin. The PDT-induced pain may originate mostly, but not entirely, in 
the extracellular compartment and perhaps require a time-delay, possibly a threshold, for 
occurrence. 
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5. Discussion 
Topical PDT is an effective treatment, and the only limiting factors are the shallow 
penetration depth of ALA and MAL, the pain and the erythema. Dealing with the pain 
associated with cutaneous PDT is a delicate balance between the reduction of discomfort 
and the risk of reduction of PDT efficiency.  
As of February 2011, a search of 228 clinical trials registered on the 
www.clinicaltrials.gov using the key words “photodynamic therapy” and/or “PDT” listed 
only 7 trials examining PDT-related pain as a primary outcome measure, out of which 3 
were in the completing phase. This number is higher than in 2008, when there was only one 
out of 181 trials listing pain as one of its primary outcome measures. Although, clearly, the 
interest in this problem is growing, more research into the causation and control of the pain 
is needed. 
 
5. 1 Control of pain during light exposure during PDT 
Many factors influence PDT-induced pain (table 4), and many possible mechanisms 
may be involved. However, its pathways remain elusive.  
5.1.1 Topical anesthesia  
Topical anesthetics, including lidocaine, are used in clinical PDT to minimize pain 
(see section 2.5.1 and table 2). Lidocaine works by blocking the fast voltage gated sodium 
(Na+) channels in cell membranes (121). Emla® cream (lignocaine 2,5% and prilocaine 
2,5%) has been investigated on AK patients, but was ineffective for pain relief during 
topical PDT (112). On the other hand, Touma et al. reported a slight reduction in ALA-PDT-
induced pain after application of 3% lidocaine hydrochloride cream on AK patients (113).  
Das and Misra (122) reported that lidocaine has singlet oxygen scavenging properties. Since 
the effectiveness of PDT depends on singlet oxygen, it was of interest to investigate the 
influence of lidocaine on PDT efficiency. We performed an in vitro study on human 
adenocarcinoma cells and in solutions (paper I). No singlet oxygen scavenging properties 
of lidocaine were observed under our conditions. The distance between the intracellular 
localization of lidocaine and the sites of photodynamic action might be too large for singlet 
oxygen scavenging to occur (paper I). This may indicate why topical anesthetics, in general, 
seem to have little effect on PDT-induced pain.  
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5.1.2 Excitation wavelength 
The role of the excitation wavelength on the pain induction was studied. 
Photobleaching of PpIX during light exposure is an indicator of molecular oxygen 
consumption, and, thus, PDT efficiency (123). According to its absorption spectrum, PpIX 
can be excited by light of different wavelengths with different penetration depths (figure 2). 
Even light from computer/tv monitors emitting in red-green-blue, may potentially, activate 
ALA-PpIX (124). Optimum activation, however, is achieved with blue light at 407-420 nm 
(125). Unfortunately, blue light does not penetrate deep into the skin. Red light penetrates 
deeper but excites PpIX less efficiently. Only a limited number of publications have 
evaluated the use of different wavelengths with regard to PDT-induced pain. Red light was 
more painful than green light in the treatment of solar keratosis (88) and Bowen’s disease 
(90). In our study (paper III), we used an innovative method for direct comparison of violet 
and red light. Both ALA and MAL were used to see if the up-take mechanism and/or the 
PpIX localization have any influence. Topical ALA-PDT with blue light required longer 
exposure times to induce pain and gave less erythema as compared with topical ALA-PDT 
with red light. For MAL-PDT such differences were not observed. These findings are in 
agreement with a recent publication on MAL-PDT of photodamaged skin with blue and 
red light, where no difference in treatment outcome and/or side effects was found (91).  
In the case of superficial lesions, the use of violet light with either MAL or ALA is beneficial 
as it provides good treatment outcomes and low pain levels. For thick lesions, deeper 
penetrating red light, with either ALA or high concentrations of MAL, is recommended as 
it ensures good treatment outcomes. However, the pain is likely to be larger than with 
violet light.  
5.1.3 PpIX level 
The influence of the PpIX concentration on the severity of PDT-induced pain is an 
unresolved question. A positive correlation between PDT-induced pain and PpIX level was 
observed in AK patients treated with MAL-PDT (68). No correlation between PpIX level 
and pain was seen in healthy human volunteers during ALA-PDT (45) and in AK, BCC and 
BD patients treated with ALA-PDT (64;69) and MAL-PDT (64). Moreover, a difference in 
pain experience between BD and BCC patients was reported when the PpIX levels were 
similar (43), suggesting that factors other than PpIX level, e.g. PpIX distribution, are 
important. Algermissen et al. (70) suggested that it is the PpIX distribution in the lesion and 
not the intensity of the PpIX fluorescence that determines the intensity of pain. All of the 
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above-mentioned studies employed one of the numeric rating scales (pain intensity 
numeric rating scale (PI-NRS), visual analogue scale (VAS) or pain logger device) to 
determine the intensity of the observed pain. The numeric rating scales range from 0 (= no 
pain) to 10 (= worst imaginable pain) where patients are asked to rate their discomfort 
during (pain logger device) or after the illumination (VAS, PI-NRS).  
5.2 Pain assessment 
In our studies we used a novel approach for measuring the PDT-induced pain: we 
measured time in seconds from the beginning of the light exposure till the onset of pain. 
This approach brings a new dimension to the pain assessment, since it is easier to 
determine whether or not one feels pain, than to describe the level of felt discomfort on a 
numerical scale, often as a recollection after the end of PDT session. This method is reliable 
and reproducible since every volunteer serves as his own control. The time for pain to 
occur on the test spots is measured against the time for pain to occur on control spots on 
the same person thus, eliminating the problem of different personal pain thresholds.  
The results of our study (paper IV) on 10 healthy volunteers, during ALA-PDT, 
show a correlation between PpIX levels and induction of the pain. Considering that the 
majority of studies using numeric methods for pain assessment report no correlation 
between PpIX level and pain, and that our method for pain determination reflects the time-
course of the onset of pain, it is probable that the PpIX level is more predictive of the length 
of the pain sensation rather than the intensity of it.  
5.3 The influence of skin penetration enhancers on pain 
One of the rate-limiting factors in the production of ALA-induced PpIX is the 
penetration of ALA through the stratum corneum and then through the plasma membrane 
of neoplastic cells. In order to increase the penetration depth of ALA into tissue, several 
methods have been proposed, such as different formulations with penetration enhancers 
(e.g. DMSO, EDTA, azone, glycolic acid or oleic acid) (126), mechanical methods (curettage, 
ultrasound, iontophoresis, electroporation and electrophoresis) (127), and chemical 
derivatization of ALA (23;38).The use of chemical substances as penetration enhancers has 
to be well balanced as they may potentially interact with the applied prodrug (128), result 
in skin saturation, thus reducing prodrug penetration (66) or influence the important 
oxygen supply (129). Mechanical methods for improving drug penetration into skin include 
removal of stratum corneum by tape stripping, curettage, debulking, microdermabration or 
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laser ablation (126). However, these techniques, although effective, are often painful and 
lead to bleeding and/or crusting (130).  
 The use of microneedles for mechanical penetration enhancement proved to be 
successful and did not evoke additional side effects (paper IV). Stratum corneum is difficult 
to penetrate for both ALA and MAL, and since our studies were performed on healthy skin 
of the volunteers, 24 hours application times were used to ensure that an amount of 
prodrug sufficient for photosensitization would penetrate through the stratum corneum 
barrier.  
The applied microneedles were microscopic polymer spikes attached to a square base 
(figure 1, paper IV).The base ensured that the microneedles did not penetrate deeper than 
to a pre-determined depth (~ 600 μm). The application of microneedles was judged by the 
volunteers as painless. It increased the skin permeation for up to two hours (as can be 
concluded from transepidermal water loss measurements, paper IV, figure 5). Our use of 
healthy human skin distinguishes this study from others. Although the use of microneedles 
for improvement of transepidermal drug delivery is not a new concept, previous studies 
were carried out on mouse skin (131), which differs significantly from human skin by being 
much thinner. The obtained conclusions therefore can not be directly transferred into 
clinical settings (132). Our results (paper IV) demonstrate the effectiveness of microneedles 
as a mechanical improvement of transdermal delivery of ALA and MAL after short 
incubation times (4 h). In addition, application of microneedles was painless, did not 
increase the PDT-related pain or erythema. Moreover, a possible saturation of the heme 
biosynthesis pathway was reached, thus allowing reduction of ALA and MAL 
concentrations, resulting in potential decrease of costs per patient. 
 These findings support a new trend emerging in the field of PDT. PDT needs to be 
efficient, patient- and clinician-friendly by minimizing cost and time, and recently, also 
ambulatory (133;134).  
5.3 PDT-induced erythema  
Although many authors mention erythema as one of the most common side effects 
of topical PDT (35;71;124), there are very few studies directly measuring/monitoring PDT-
induced erythema. In 2004, Clark et al. described erythemal response after topical ALA-
PDT in 10 healthy subjects (135). Their results showed a peak of erythema within 1-2 h after 
light exposure. Our results, however, do not support this finding. The erythemal response 
observed in our studies peaked either immediately after the light exposure (paper IV) or 
within half an hour (paper III). The reason for these discrepancies may be differences 
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between the site of measurements (back and lower leg vs forearm), or well known 
interpersonal variations between volunteers (136). Since Clark et al. did not find any 
correlation between the extent of erythema and treatment site, nor between erythema and 
types of light sources used (135), the reason for the discrepancy seems to be interpersonal 
variations.  
Attempts to reduce erythema with natural compounds, such as (R)L-sulforaphane 
(SF) derived from broccoli sprouts and other cruciferous vegetables, are safe. However, 
since introducing new chemical compounds into the course of treatment may affect the 
PDT outcome, we investigated the influence of SF addition on ALA-PpIX production and 
bleaching in solutions, cells (A431 cell line) and human skin (paper II). To our surprise, 
adding SF not only maintained the effectiveness of PpIX photobleaching, but increased the 
PpIX production in human skin. SF was chosen for our study due to its anti-erythemal 
properties, although it has also been shown to enhance detoxification of carcinogens (137), 
block chemically induced carcinogenesis in animals (138), inhibit tumor growth (139), arrest 
cell cycle progression and enhance apoptosis (140). Our data, together with all these 
findings strongly suggest beneficial effects of incorporating SF into the course of PDT 
treatment.   
5.4 Real-time PDT measurements 
Bioimpedance measurements of human skin during light exposure revealed a time 
delay in pain sensation occurrence (paper V). This delay can be explained by a threshold of 
damage that has to be reached before pain occurs. Thus, an increase in temperature during 
light exposure may be needed to activate TRPV1 channels (capsaicin receptors) that lead to 
nerve responses (100), or there may be a time delay needed between hydrogen peroxide 
(H2O2)-induced mast cells degranulation and histamine release which leads to activation  of 
C-fibers (141).  
A duality of the PDT-induced pain was documented by Lipson and Baldes (19), Holmes 
et al. (95), and recently, by us (paper V). The first PDT-pain component is an early sensation 
of stinging - possibly neurogenic. The following burning sensation is a late, inflammatory 
process. The biompedance measurements at low frequency at about 7 min. of light 
exposure (paper V) revealed a plateau, which may reflect a shift from vasoconstriction (the 
narrowing of blood vessels) to vasodilatation (the widening of blood vessels) of small 
vessels; or a change in the tissue response from early, neurogenic, to late, inflammatory, 
reactions. This observation is in agreement with the reports from Phase III clinical trials on 
ALA-PDT treatment of nonhyperkeratotic actinic keratoses of the face and scalp on 243 
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subjects, where the peak of stinging and burning was observed approximately 6 min into 
the light exposure (35). Although an exact explanation remains speculative, the current 
state of knowledge may be summarized as follows.  PDT-induced pain response can be 
divided into an early and a late phase (figure 10). Early response starts with the light 
activation of PpIX (hν-excitation light) that leads to 1) production of reactive oxygen 
species, including singlet oxygen (1O2) and hydrogen peroxide (H2O2), 2) damage to 
neoplastic cells and/or nerve cells resulting in leakage of their content into the extracellular 
space, and 3) degranulation of mast cells and release of, among others, histamine. The 
length of the early response can vary from few seconds to few minutes depending on PpIX 
concentration, localization, distribution inside the lesion and other parameters shown in 
table 4. The pain signal is possibly triggered by an unknown mediator/change taking place 
mainly in the extracellular compartments of the tissue. Whether the strength of the pain 
signal influences the extent of the inflammation is not known. The late response starts with 
the release of mediators of inflammation from degranulated mast cells and/or damaged 
cells.   
 
Figure 10. Possible PDT-induced pain mechanisms. See text for details.  
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5. Conclusions 
Pain is strongly individual, difficult to quantify, describe and, most of all, compare. 
The goal of this thesis was to investigate the influence of factors that may be used to reduce 
the pain on the treatment efficiency (lidocaine and (R)L-sulforaphane), as well as possible 
influences on pain sensations of  factors potentially modulating the treatment (violet/red 
excitation light and microneedles), and finally to shed light on the photodynamic action 
and pain mechanism through real-time measurements of skin bioimpedance during light 
exposure. The results of our studies demonstrated that:  
1. Lidocaine, although being a singlet oxygen quencher, does not influence 
the PDT efficiency in vitro. Our results suggest a difference in intracellular 
localization of the lidocaine activity and photodynamic action.  
2. The anticancer and anti-erythemal drug, SF, increased PDT efficiency by 
increasing ALA-PpIX production.  
3. Violet light should be used with MAL or ALA for superficial lesions, 
while red light should be used with ALA for thicker lesions.  
4. Red light induced more pain than violet during PDT with ALA, while 
there was no difference in pain during PDT with MAL. 
5. The use of microneedles prior to ALA- and MAL-PDT allowed for 
reduction of the prodrug concentration and application time without 
increase in side effects.  
6. A decrease in skin impedance both at 10 Hz and at 100 kHz may imply 
that the pain-inducing changes take place mainly in the tissue 
extracellular compartments.  
These findings suggest than careful adjustment of the excitation light wavelength and the 
type of prodrug to the thickness of the treated lesion, and use of microneedles and SF for 
improved PpIX production can reduce PDT-induced pain and potentially improve the 
treatment outcome.  
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6. Future prospects 
The results presented in this thesis show that the initial photodynamic damage 
probably takes place at a distance from nerve endings. Thus, the resulting pain signal is 
likely not mediated through Na+ channels. Moreover, the pain seems to arise faster the 
deeper the photodynamic action occurs (since deeply penetrating red light is more painful 
than shallow penetrating violet light). Furthermore, the PpIX intra-tissue distribution 
seems to play a larger role than the PpIX concentration. All above-mentioned facts point to 
the importance of the PpIX localization. 
The chemical structure of the prodrug influences its penetration and 
pharmacokinetics (44;142). Moreover, ALA and MAL are taken up into cells by different 
mechanisms (44), and the uptake of MAL does not inhibit the uptake of ALA (45). 
Therefore, it would be interesting to investigate a mixture of ALA and MAL with respect to 
PDT efficiency and sensation of pain.  
Furthermore, since ALA and MAL penetrate to different depths, (in contrast to 
ALA, MAL does not give a systemic effect after topical application (39)) it could be 
beneficial to expose lesions first to blue light and subsequently to red light. This procedure 
might cause ‘layer- by- layer’ killing of cells and bleaching of the PpIX and prevent rapid 
depletion of oxygen. It might also prevent hypoxia and minimize the pain sensation. 
Additional application of a vasodilatating drug on the outside margin of the treated lesion 
(healthy surrounding tissue) could provide an undisturbed oxygen flow, even at high 
fluence rates.  
It seems worthwhile to investigate further the relationship between light intensity 
and pain. Why do high fluence rates induce pain and not low fluence rates? Light delivery 
at low fluence rates allows reoxygenation during the light exposure, thus avoiding oxygen 
depletion and hypoxia. Tromberg et al. (143) distinguished three consecutive processes 
during light exposure during PDT: 1) initial consumption of oxygen and production of 
singlet oxygen, 2) local hypoxia and 3) ischemia. When molecular oxygen is depleted and 
the tissue reaches hypoxia, excited PpIX may react with other biomolecules leading to 
generation of, among others, pain mediators.  
We have shown that pain sensation occurs with a time-delay after the start of the 
light exposure and that the onset of pain is accompanied by a detectable drop in 
bioimpedance. This time delay raises a range of questions. Is it related to the time needed 
for skin temperature to rise above the level of thermal nerve activation, or is it needed for 
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enough damage to the neoplastic cells to occur, resulting in leakage of cell content and 
beginning of an inflammatory reaction?  
Possibly more than one nerve cell membrane must be broken before a big enough 
leakage of neurotransmitters into the extracellular space occurs, causing activation of 
neighboring nerve cells that leads to pain signals. Activation of nerve cells by histamine 
released from degranulated mast cells has been shown to be involved in the early phase of 
PDT-pain response (99). Mast cells can undergo different types of degranulation processes, 
some of which involve partial release of the granule matrix of mast cells into the 
extracellular space (144). Perhaps the time needed for PDT-induced pain to occur reflects 
the time needed for degranulation of mast cells and release of histamine. 
There might also be a yet unknown product of the secondary photochemical 
reactions ongoing during light exposure in human skin, and the time delay may be needed 
for the concentration of such a product to become high enough for nerve cell 
activation/damage to occur. It is not unlikely that such a process could require specific 
conditions, e.g. a given level of hypoxia. 
By identifying the mechanism behind the observed threshold/time delay, we may 
improve our understanding of PDT-induced pain and ultimately come closer to an efficient 
way of reducing pain during treatment. 
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